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Pneumocystis jirovecii colonization has been associated with
non-acquired immune deﬁciency syndrome (AIDS) pulmonary
comorbidity. We used spirometry to measure pulmonary
function and analyzed oral wash specimens by quantitative
polymerase chain reaction (PCR), targeting the large mitochon-
drial ribosomal subunit. For sensitivity control, a blinded sub-
sample was subjected to touch-down PCRs, targeting both large
and small ribosomal subunits and the major surface glycopro-
tein. Pneumocystis jirovecii deoxyribonucleic acid (DNA) was
detected in 1 of 156 (95% conﬁdence interval, .1%–3.5%) viro-
logically suppressed human immunodeﬁciency virus (HIV)-
infected individuals conﬁrmed by all PCR methods. Thus,
prevalence of P jirovecii colonization was low and unlikely to
be a major cause of pulmonary comorbidity in this group of
well treated HIV-infected individuals.
Keywords. airway obstruction; HIV-1; Pneumocystis;
colonization.
With the widespread use of combination antiretroviral therapy
(cART), the incidence of Pneumocystis pneumonia (PCP) has
decreased [1], albeit PCP remains a common acquired immune
deﬁciency syndrome (AIDS)-deﬁning opportunistic infection
[2]. Moreover, colonization with P jirovecii has been linked to
non-AIDS pulmonary comorbidity in human immunodeﬁcien-
cy virus (HIV)-infected individuals in the cART era [3].
Chronic obstructive pulmonary disease (COPD) is more
prevalent in individuals infected with HIV compared with un-
infected individuals [4], but the underlying mechanisms are un-
clear. In the pre-ART era, PCP was recognized as a risk factor
for subsequent airway obstruction [5]. Furthermore, evidence
from the early cART era suggested that P jirovecii colonization
may be an independent risk factor for HIV-associated COPD [6].
However, studies of P jirovecii colonization were unable to deter-
mine causality.
The prevalence of P jirovecii colonization has been investigat-
ed in several HIV-infected and uninfected populations. In the
early cART era, the prevalence of colonization varied from
10% to 70% depending on the population studied [3]. However,
most studies included HIV-infected individuals with profound
immunodeﬁciency, respiratory symptoms, or AIDS [3].
In this study, we determined the prevalence of P jirovecii col-
onization in a cohort of cART-treated HIV-infected individuals
with and without airway obstruction using 2 independent poly-
merase chain reaction (PCR) methods and spirometry. We hy-
pothesized that P jirovecii colonization would be detectable even
in well treated individuals and a higher prevalence would be
found in those with COPD.
METHODS
Patients
This study was approved by the Committee on Health Research
Ethics of the Capital Region of Denmark (protocol no. H-8-
2014-004) and performed in accordance with the Helsinki
Declaration. Oral and written informed consent was obtained
from all patients before participation. The study was registered
at clinicaltrials.gov (NCT02382822) as part of the ongoing
Copenhagen Comorbidity Study in HIV infection. We initially
planned to study colonization longitudinally, but, due to the re-
sults, only a cross-sectional was performed. Inclusion period
was from May to October 2015. All participants were recruited
from the University of Copenhagen outpatient clinics at Rigsho-
spitalet and Hvidovre Hospital.
Data Collection
Information about HIV-related variables including CD4 T-cell
count, HIV viral load, previous PCP, intravenous drug use,
and coinfection with hepatitis C virus were retrieved from
patient records. All participants completed a questionnaire
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that included information on tobacco exposure and use of
inhaled medication.
Spirometry
Spirometry was performed using an EasyOne ultrasonic spiro-
meter (ndd Medizintechnik, Zürich, Switzerland) in accordance
with American Thoracic Society (ATS)/European Respiratory
Society (ERS) guidelines [7]. For bronchodilation (in patients
with a ratio between forced expiratory volume in 1 second
and forced vital capacity [FEV1/FVC] <0.7), 400 µg of salbuta-
mol was given by inhalation (Ventoline Diskus; Glaxo Smith
Kline, Middlesex, United Kingdom). Airway obstruction was
deﬁned according to the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) criteria for COPD and deﬁned as a
post-bronchodilator FEV1/FVC <70% [8]. Chronic obstructive
pulmonary disease was also assessed by the lower limit of nor-
mal (LLN) (ie, ﬁfth percentile) of the FEV1/FVC ratio according
to ATS/ERS recommendations using Global Lung Function Ini-
tiative prediction equations [9].
Quantitative Real-Time Polymerase Chain Reaction (PCR) and Touch-
Down PCRs
Oral wash was collected after gargling 10 mL saline (9 mg/mL)
for 1 minute. Samples were either analyzed on the same day or
stored at 5°C overnight before analysis. First, 500 µL sample was
digested with 21 µL proteinase K (Roche, Basel, Switzerland) at
56°C for 30 minutes followed by PCR. For the quantitative PCR
(qPCR), sensitivity was based on the use of 0.5 mL oral wash
sample that was vortexed to secure equal distribution of cells
but not further processed before proteinase K treatment.
Using an in-house protocol and the BD MAX Platform
(Becton-Dickinson, Durham, NC), P jirovecii deoxyribonucleic
acid (DNA) was determined by qPCR targeting the large sub-
unit of mitochondrial (mtLSU) ribosomal ribonucleic acid
(rRNA) (Supplementary Material 1). Blinded for previous re-
sults, one quarter of the samples (N = 39) were also tested for
P jirovecii DNA in a reference laboratory (Department of Mi-
crobiology and Infection Control, Statens Serum Institut)
using touch-down PCRs targeting mtLSU rRNA, mitochondrial
small subunit rRNA, and the major surface glycoprotein (MSG)
(see Supplementary Material 1). Both PCR tests were done on
the clinical sample material that had been stored at −20°C for
additional testing, thus DNA extraction was repeated for the re-
peat test.
Data Analysis
Comparison of individuals with airway obstruction versus those
without airway obstruction were done using 2-sample Student’s
t tests or Mann-Whitney U test for continuous data, as appro-
priate. Fisher′s exact test was used for categorical data. The 95%
binomial conﬁdence intervals (CIs) for colonization prevalence
were calculated based on the Wilson method using the “binom”
package in R. The statistical software package R (V.3.2.0) was
used [10].
RESULTS
One hundred ﬁfty-eight participants were recruited, including 44
with airway obstruction and 114 without airway obstruction. Two
participants were not receiving cART and omitted from further
data analysis (Table 1). Both were negative for P jirovecii DNA.
Furthermore, 2 participants had detectable HIV viral replication
(222 and 223 copies/mL) corresponding to a viremic bleep and
recently initiated cART, respectively, and both had fully
suppressed viral replication upon follow up. All remaining partic-
ipants had undetectable HIV viral load. HIV-infected individuals
with airway obstruction were older (P < .001) and had higher
cumulative smoking (P < .001), current smoking (P < .001), and
inhaled corticosteroid use (P = .03). The groups were similar
with regard to sex distribution, ethnicity, current CD4+ T-cell
count, CD4 nadir, and cART use. Most of the participants with
airway obstruction had either mild or moderate airway obstruc-
tion, and only 5 were classiﬁed with severe airway obstruction
(FEV1 30%–49% of predicted) (Table 2). Consequently, 42% of
those with airway obstruction, according to the GOLD ﬁxed
ratio criteria, were identiﬁed as obstructed using the LLN criteria.
Participants with airway obstruction also had lower FVC com-
pared with individuals without airway obstruction (FVC 4.0 vs
4.5, P < .01) (Table 1).
qPCR on oral wash was carried out for every participant. No
tests showed inhibition. P jirovecii DNA was detected in only 1
of the 156 participants (0.6%; binomial 95% CI, .1–3.5). This
individual had no respiratory complaints (ie, dyspnoea, wheezing,











Age, y (SD) 58.9 (9.28) 52.2 (12.0) <.001
Male, n (%) 37 (84.1) 102 (91.1) .25
Ethnicity (white), n (%) 43 (97.7) 108 (96.4) 1.0
Duration of HIV infection, y (SD) 19.8 (8.1) 14.2 (8.5) <.001
Prior clinical AIDS 9 (20.5) 19 (17.0) .47
Current CD4, cells/µL (SD) 746 (303) 720 (264) .58
CD4 nadir, cells/µL (IQR) 177 (94–336) 260 (120–383) .20
Undetectable viral load, n (%) 44 (100) 110 (98.2) 1.0
HCV coinfection, n (%) 4 (9.0) 4 (3.5) .22
Current IDU, n (%) 0 (0) 1 (0.9) 1.0
Current smoking, n (%) 20 (48.8) 21 (19.3) <.001
Cumulative pack years, y (IQR)b 24.0 (12.5–35) 4.0 (0–17.0) <.001
Inhaled corticosteroid use, n (%) 5 (11.4) 3 (2.7) .03
Previous PCP, n (%) 5 (11.4) 6 (5.3) .7
Abbreviations: AIDS, acquired immune deficiency syndrome; HCV, hepatitis C virus; HIV,
human immunodeficiency virus; IDU, intravenous drug use; IQR, interquartile range; PCP,
Pneumocystis pneumonia; SD, standard deviation.
a Characteristics were summarized using mean (SD) or median (IQR or range). P values were
calculated using Student’s t tests or Mann-Whitney U tests, as appropriate, or Fisher’s exact
test.
b Cumulative pack years were calculated for entire cohort.
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or coughing) nor any other clinical or immunologic evidence con-
sistent with PCP. For conﬁrmation of qPCR results, frozen sam-
ples from patients with and without airway obstruction (16 and 23
random samples, respectively) were subsequently assessed by con-
ventional PCR blinded to previous results. In this analysis, the
same individual was identiﬁed as being colonized, and all others
were negative for P jirovecii DNA.
Seventy-three participants had 1 or more potential risk factors
for colonization including airway obstruction (28%), current
smoking (26%), previous PCP (7%), inhaled corticosteroid use
(5%), or current CD4 count <200 cells/µL (2%).
DISCUSSION
Despite the presence of potential risk factors for colonization,
the prevalence of P jirovecii colonization was surprisingly
low in this study population of virologically suppressed HIV-
infected individuals and not related to airway obstruction.
Contrary to its relationship with PCP, the association be-
tween immune function and P jirovecii colonization is unclear.
A previous study in 30 HIV-uninfected individuals was not able
to detect P jirovecii, but it detected the fungus in 8 of 50 unin-
fected individuals with COPD [11]. One study found that low
CD4 count was associated with colonization [12], whereas
CD4 was not a risk factor in another study [13]. We tested
HIV-infected individuals on cART with undetectable viral rep-
lication and high CD4 counts, which may explain the low prev-
alence in our study compared with previous studies [3].
Other possible explanations for the low prevalence in this
study may include geographic area. Thus, one study found city
of residence to be a risk factor for colonization [13]. In addition,
seasonal variation may explain differences in colonization preva-
lence, because PCP has been associated with higher mean
temperatures [14]. Although we assessed colonization from a
restricted geographical area between May and October, it seems
unlikely that these factors alone explain the low prevalence.
Another explanation for the low prevalence may include the
methods applied. Other studies assessed P jirovecii colonization
using autopsies, bronchoalveolar lavage (BAL) ﬂuid, induced
sputum, or oral wash specimens [3]. Furthermore, several differ-
ent methods have been used including conventional PCR, real-
time, or nested PCR. Oral wash had 88% sensitivity and 85%
speciﬁcity for PCP using qPCR targeting the MSG and direct
microscopy on BAL or induced sputum as the gold standard
[15]. A nested PCR may yield a better sensitivity, but, on the
other hand, it may not take into account false-positive results
and may amplify a potential contamination. Quantitative PCR
and nested PCR have been compared for diagnosis of PCP
showing similar sensitivity (94% vs 94%) and higher speciﬁcity
for qPCR (94% vs 81%) [16]. However, diagnostic performanc-
es for PCP may not be applicable for colonization. To minimize
the risk of underestimating the prevalence due to methodolog-
ical errors, we used both qPCR and conventional PCR. Impor-
tantly, identical results were obtained using both of these
methods. Because the low prevalence of P jirovicii positives
was unexpected, a subset of the specimens was re-examined
in a reference laboratory where 3 independent targets were de-
tected as part of an accredited analysis. We initially re-examined
one quarter of the samples. Because these results were identical
to the qPCR results, we found it unnecessary to re-examine all
samples.
Pneumocystis jirovecii colonization has been associated with
various non-AIDS pulmonary conditions, ie, COPD and intersti-
tial lung disease, although causal relationships have not been es-
tablished [3]. Several studies have suggested a higher incidence of
COPD in HIV-infected individuals than in uninfected individu-
als [4], but the underlying mechanism(s) have not been estab-
lished. We initially planned a longitudinal study aimed at
studying a causal relationship between P jirovecii colonization
and development of airway obstruction. Based on the low prev-
alence of colonization, we were not able to carry out such a study.
The present study has strengths and limitations. To our
knowledge, we have conducted the largest population study of
P jirovecii colonization in individuals infected with HIV, and 2
different methods were used to detect colonization. Due to eth-
ical considerations, only oral washings, and not samples from
the lower airways, were sampled. The lack of lower respiratory
tract sample may have compromised the ability to detect P jir-
ovecii. However, previous studies found high detection rate in
oral washes of HIV-infected patients [6]. Finally, the study
was restricted to a limited geographical area, and it may not
be representative of other parts of the world.












FEV1, l (SD) 2.6 (0.8) 3.5 (0.7) <.001
FEV1, percent predicted (SD) 72.9 (19.5) 91.9 (11.6) <.001
FVC, l (SD) 4.0 (1.1) 4.5 (0.8) <.01
FVC, per cent predicted (SD) 88.4 (19.8) 92.7 (10.9) .174
FEV1/FVC ratio (SD) 63.2 (7.5) 78.2 (6.3) <.001
GOLD Stage
FEV1≥ 80% predicted 15 (34.1) 98 (87.5) <.001
FEV1 50%–79% predicted 23 (52.3) 14 (12.5)
FEV1 30%–49% predicted 4 (9.0) 0 (0)
FEV1 <30 predicted 2 (4.5) 0 (0)
Pneumocystis jirovecii
colonization, n (%)
0 (0) 1 (0.9) 1
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; SD,
standard deviation.
The FEV1 percent predicted was calculated using Global Lung Function Initiative prediction
equations.
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CONCLUSIONS
In conclusion, the prevalence of P jirovecii colonization was low
and may indicate declining prevalence of P jirovecii colonization
in HIV-infected individuals on cART. Based on the data at
hand, P jirovecii colonization does not appear to be a major
contributor to the development of COPD in well treated,
HIV-infected individuals. However, longitudinal studies in
populations with a higher prevalence of P jirovecii colonization
and the use of lower respiratory tract specimens would be need-
ed to draw conclusions about a causal relationship between
P jirovecii colonization and pulmonary disease.
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